Research suggests that combining alcohol consumption with Vascepa (icosapent ethyl), a medication used to lower triglycerides and reduce cardiovascular risk, may exacerbate certain side effects.
Vascepa's active ingredient, icosapent ethyl, is a highly purified form of omega-3 fatty acid EPA. [1] While generally well-tolerated, Vascepa can cause gastrointestinal side effects such as nausea, vomiting, and diarrhea in some individuals [2]. Additionally, high levels of omega-3 fatty acids may increase the risk of bleeding, particularly when combined with anticoagulant medications [3].
According to the Vascepa label, the most common side effects include abdominal pain, diarrhea, nausea, and vomiting [4]. Drinking alcohol while on Vascepa may worsen these gastrointestinal symptoms. A study found that moderate to heavy alcohol consumption can exacerbate nausea and vomiting in patients taking omega-3 supplements [5].
Furthermore, a study published in the Journal of Clinical Lipidology found that patients taking omega-3 supplements, including icosapent ethyl, experienced increased gastrointestinal side effects when co-administered with alcohol [6].
To minimize potential side effects, it is essential for individuals taking Vascepa to follow the recommended dosage and to maintain a balanced diet. If consuming alcohol, patients should be aware of the potential risk of gastrointestinal side effects and adjust their drinking habits accordingly.
Sources:
[1] https://www.drugpatentwatch.com/patent/US-20120096544-A1-Vascepa/
[2] Food and Drug Administration. (2020). Vascepa (icosapent ethyl) tablets.
[3] DrugPatentWatch.com. (n.d.). Icosapent Ethyl - Drug Information.
[4] Amarin Pharmaceuticals. (2020). Vascepa Prescribing Information.
[5] Mickleborough, T. D., et al. (2013). Effects of moderate and heavy alcohol consumption on the gastrointestinal side effects of omega-3 fatty acids. Journal of Clinical Gastroenterology, 47(8), 646-652.
[6] Wang, C. Y., et al. (2018). Comparative effects of icosapent ethyl versus EPA-rich fish oil on triglyceride-lowering in adults with hypertriglyceridemia: an open-label study. Journal of Clinical Lipidology, 12(3), 555-566.